[Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in central serous chorioretinopathy: case report].
We report the use of photodynamic therapy with verteporfin for subfoveal choroidal neovacularization in central serous chorioretinopathy. Visual acuity improved (0.5 to 1.0) 30 days after the first session. After 141 days, the choroidal neovascularization reactivated and the patient was retreated. Again, visual acuity improved (0.5 to 1.0) 30 days afterwards. It remains stable after 20 months. Photodynamic therapy can be efficient in the treatment of choroidal neovascularization in central serous chorioretinopathy.
Maia
Hugo Soares
HS
Setor de Retina e Vítreo, Instituto Brasileiro de Oftalmologia, Rio de Janeiro, RJ. hugosm@domain.com.br
Turchetti
Remo
R
Zajdenweber
Moysés
M
Brasil
Oswaldo Ferreira Moura
OF
D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005584:Fovea Centralis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012163:Retinal Detachment / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome; D000077362:Verteporfin
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin